These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 25755212

  • 1. Efficacy response in CF patients treated with ivacaftor: post-hoc analysis.
    Konstan MW, Plant BJ, Elborn JS, Rodriguez S, Munck A, Ahrens R, Johnson C.
    Pediatr Pulmonol; 2015 May; 50(5):447-55. PubMed ID: 25755212
    [Abstract] [Full Text] [Related]

  • 2. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S, Sinha IP, Dwan K, Echevarria C, Schechter M, Southern KW.
    Cochrane Database Syst Rev; 2015 Mar 26; (3):CD009841. PubMed ID: 25811419
    [Abstract] [Full Text] [Related]

  • 3. Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience.
    Durmowicz AG, Witzmann KA, Rosebraugh CJ, Chowdhury BA.
    Chest; 2013 Jan 26; 143(1):14-18. PubMed ID: 23276841
    [Abstract] [Full Text] [Related]

  • 4. The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation.
    Seliger VI, Rodman D, Van Goor F, Schmelz A, Mueller P.
    J Cyst Fibros; 2013 Dec 26; 12(6):706-13. PubMed ID: 23628510
    [Abstract] [Full Text] [Related]

  • 5. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST).
    McKone EF, Borowitz D, Drevinek P, Griese M, Konstan MW, Wainwright C, Ratjen F, Sermet-Gaudelus I, Plant B, Munck A, Jiang Y, Gilmartin G, Davies JC, VX08-770-105 (PERSIST) Study Group.
    Lancet Respir Med; 2014 Nov 26; 2(11):902-910. PubMed ID: 25311995
    [Abstract] [Full Text] [Related]

  • 6. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.
    Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS, VX08-770-102 Study Group.
    N Engl J Med; 2011 Nov 03; 365(18):1663-72. PubMed ID: 22047557
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.
    Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, Rubenstein RC, Higgins M, VX11-770-110 (KONDUCT) Study Group.
    Lancet Respir Med; 2015 Jul 03; 3(7):524-33. PubMed ID: 26070913
    [Abstract] [Full Text] [Related]

  • 8. Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.
    Rowe SM, McColley SA, Rietschel E, Li X, Bell SC, Konstan MW, Marigowda G, Waltz D, Boyle MP, VX09-809-102 Study Group.
    Ann Am Thorac Soc; 2017 Feb 03; 14(2):213-219. PubMed ID: 27898234
    [Abstract] [Full Text] [Related]

  • 9. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
    Davies J, Sheridan H, Bell N, Cunningham S, Davis SD, Elborn JS, Milla CE, Starner TD, Weiner DJ, Lee PS, Ratjen F.
    Lancet Respir Med; 2013 Oct 03; 1(8):630-638. PubMed ID: 24461666
    [Abstract] [Full Text] [Related]

  • 10. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.
    Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordoñez CL, Geller DE, VX 08-770-104 Study Group.
    Chest; 2012 Sep 03; 142(3):718-724. PubMed ID: 22383668
    [Abstract] [Full Text] [Related]

  • 11. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Sass LA, Tullis E, McKee CM, Moskowitz SM, Robertson S, Savage J, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Taylor-Cousar JL, VX16-445-001 Study Group.
    N Engl J Med; 2018 Oct 25; 379(17):1612-1620. PubMed ID: 30334692
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
    Ratjen F, Hug C, Marigowda G, Tian S, Huang X, Stanojevic S, Milla CE, Robinson PD, Waltz D, Davies JC, VX14-809-109 investigator group.
    Lancet Respir Med; 2017 Jul 25; 5(7):557-567. PubMed ID: 28606620
    [Abstract] [Full Text] [Related]

  • 13. Effectivenesss of ivacaftor in severe cystic fibrosis patients and non-G551D gating mutations.
    Salvatore D, Carnovale V, Iacotucci P, Braggion C, Castellani C, Cimino G, Colangelo C, Francalanci M, Leonetti G, Lucidi V, Manca A, Vitullo P, Ferrara N.
    Pediatr Pulmonol; 2019 Sep 25; 54(9):1398-1403. PubMed ID: 31237430
    [Abstract] [Full Text] [Related]

  • 14. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone EF, Plant BJ, Prais D, Ramsey BW, Taylor-Cousar JL, Tullis E, Uluer A, McKee CM, Robertson S, Shilling RA, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Rowe SM, VX16-659-101 Study Group.
    N Engl J Med; 2018 Oct 25; 379(17):1599-1611. PubMed ID: 30334693
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation.
    Davies JC, Wainwright CE, Canny GJ, Chilvers MA, Howenstine MS, Munck A, Mainz JG, Rodriguez S, Li H, Yen K, Ordoñez CL, Ahrens R, VX08-770-103 (ENVISION) Study Group.
    Am J Respir Crit Care Med; 2013 Jun 01; 187(11):1219-25. PubMed ID: 23590265
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation.
    De Boeck K, Munck A, Walker S, Faro A, Hiatt P, Gilmartin G, Higgins M.
    J Cyst Fibros; 2014 Dec 01; 13(6):674-80. PubMed ID: 25266159
    [Abstract] [Full Text] [Related]

  • 17. CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy.
    Guerra L, D'Oria S, Favia M, Castellani S, Santostasi T, Polizzi AM, Mariggiò MA, Gallo C, Casavola V, Montemurro P, Leonetti G, Manca A, Conese M.
    Pediatr Pulmonol; 2017 Jul 01; 52(7):900-908. PubMed ID: 28445004
    [Abstract] [Full Text] [Related]

  • 18. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
    McGarry ME, Illek B, Ly NP, Zlock L, Olshansky S, Moreno C, Finkbeiner WE, Nielson DW.
    Pediatr Pulmonol; 2017 Apr 01; 52(4):472-479. PubMed ID: 28068001
    [Abstract] [Full Text] [Related]

  • 19. Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor.
    Borowitz D, Lubarsky B, Wilschanski M, Munck A, Gelfond D, Bodewes F, Schwarzenberg SJ.
    Dig Dis Sci; 2016 Jan 01; 61(1):198-207. PubMed ID: 26250833
    [Abstract] [Full Text] [Related]

  • 20. Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor.
    Fidler MC, Beusmans J, Panorchan P, Van Goor F.
    J Cyst Fibros; 2017 Jan 01; 16(1):41-44. PubMed ID: 27773592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.